Business
ProAxsis announces additional IP
ProAxsis announces additional IP.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 6667E NetScientific PLC 10 May 2017 \n\n \n \n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \n \nNetscientific Announces that successful license by portfolio company ProAxsis of additional intellectual property from The Queen's University of Belfast\n \nLondon, UK - 10 May 2017 - NetScientific Plc (AIM: NSCI, \"NetScientific\", \"the Group\"), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company ProAxsis has secured a second licensing agreement with the Queen's University of Belfast for exclusive intellectual property rights for its ProteaseTag® technology. \nProAxsis develops point of care diagnostics for the capture, detection and measurement of active protease biomarkers of respiratory disease. This technology enables the measurement of active protease biomarkers of disease, strengthening ProAxsis's intellectual property portfolio and is expected to support ProAxsis in the development of additional point of care tests and assays.\nCommenting on the news, François R. Martelet, Chief Executive Officer of NetScientific, and Chairman of ProAxsis, said: \"ProAxsis is approaching a point where it will be able to commercialize its NEATstik point of care test based on the ProteaseTags® technology. This agreement, which strengthens the Company's intellectual property portfolio, puts ProAxsis in a great position to launch further immunoassays and point of care tests and build the value of this technology.\"\nThe full text of the announcement issued by ProAxsis follows:\n \nProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen's University of Belfast for exclusive intellectual property rights for its ProteaseTag® technology. This technology enables the measurement of active protease biomarkers of disease. Following its spin out from Queen's in 2013, the two parties agreed an initial licence for the first generation of ProteaseTags®, enabling ProAxsis to commercialise its first product. This laboratory-based immunoassay for the measurement of neutrophil elastase as a biomarker of lung infection and inflammation in chronic respiratory diseases was successfully registered with a CE Mark in September 2016. \n \nCommenting on the news...